MedTrace Logo

Wearable Devices to Assess Effects of Central Nervous Medications on Physical Conditions in Patients With Sleep Problems

NCT05300386 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 52

Last updated 2022-03-29

No results posted yet for this study

Summary

Generalized anxiety disorder (GAD) and obstructive sleep apnea (OSA) are two common diseases and share similar symptoms such as anxiety, poor attention, and poor sleep quality. However, the evidence toward the association between GAD and OSA is limited. The current study aims to use wearable devices to detect comorbid OSA in newly diagnosed patients with GAD and observe the treatment response and difference in automatic nervous function in GAD and GAD/OSA groups.

Conditions

Interventions

DRUG

Escitalopram

We use Escitalopram 5\~10 mg for two groups to observe the impact of sleep apnea on the treatment of generalized anxiety disorder

Sponsors & Collaborators

  • Tri-Service General Hospital

    lead OTHER

Principal Investigators

  • Tien-Yu Chen, MD · Tri-Service General Hospital

Eligibility

Min Age
20 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-30
Primary Completion
2021-05-29
Completion
2022-01-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05300386 on ClinicalTrials.gov